American Liver Foundation funds 4 research projects in biliary atresia
The American Liver Foundation (ALF) has announced the eight winners of its 2024 Pilot Research Awards, with four of the awards going to scientist-led…
Lindsey Shapiro, PhD, Science Writer — 
Articles by Lindsey Shapiro
First-in-human trial of PBGENE-HBV for chronic hepatitis B opens
Precision Biosciences has opened a first-in-human trial testing its gene-editing therapy candidate PBGENE-HBV in people with chronic hepatitis B infections, and says data…
Aligos planning for Phase 2 trial of treatment for hepatitis B
The U.S. Food and Drug Administration (FDA) has cleared the launch of a Phase 1 drug-drug interaction study to evaluate the effects of certain drugs…
RTY-694 chosen as lead treatment candidate for liver disease PSC
Rectify Pharmaceuticals has selected the oral small molecule RTY-694 as its lead treatment candidate for primary sclerosing cholangitis (PSC) and plans are underway…
New study may explain milder liver scarring seen in Alagille syndrome
Alterations to the immune system may underlie the mild liver scarring, or fibrosis, that characterizes Alagille syndrome despite severe liver disease, according to a…
US study shows gaps in hepatitis C testing, care for women at risk
Fewer than half of reproductive-aged women with opioid use disorder in the U.S. undergo hepatitis C testing, with Black and Asian women less likely…
FDA names volixibat, for itching due to PBC, a breakthrough therapy
The U.S. Food and Drug Administration (FDA) has designated Mirum Pharmaceuticals’ oral candidate volixibat a breakthrough therapy for the treatment of itching, or…
American Liver Foundation launches free toolkit for children
The American Liver Foundation (ALF) has launched a toolkit — featuring a plush lion named Bili the Brave — to support children and families…
Abbvie pulls 2 hepatitis treatments from EU market
Abbvie has decided to permanently discontinue the marketing of antiviral treatments Exviera (dasabuvir) and Viekirax (ombitasvir/paritaprevir/ritonavir) for adults with chronic hepatitis…
Iqirvo approved in UK for adults with PBC, problems with UDCA
U.K. regulators have approved Iqirvo (elafibranor) for adults with primary biliary cholangitis (PBC) who fail to respond to or cannot tolerate first-line…